# US 2012/0252845 A1 · Composition for sustained drug delivery comprising geopolymeric binder

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2012/0252845 A1
- Document ID: US20120252845A1
- Status: Published application
- Kind: A1
- Application number: 13/319,201
- Filed: 2010-05-07
- Published: 2012-10-04
- Earliest claimed: 2009-05-08
- Assignees: Emplicure AB
- Inventors: Hakan Engqvist
- Web page: https://patentgrep.com/patent/US20120252845A1

## CPC

- A61K 47/02: Inorganic compounds
- A61K 9/1611: {Inorganic compounds}
- A61K 31/4468: having a nitrogen directly attached in position 4, e.g. clebopride, fentanyl
- A61P 25/04: Centrally acting analgesics, e.g. opioids
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The present invention relates to a sustained release medical composition comprising an active pharmaceutical ingredient and a geopolymeric binder. Preferably the active pharmaceutical ingredient is combined with the geopolymeric binder during the formation of that binder.

## Claims

### Claim 1

A sustained release pharmaceutical composition comprising an active pharmaceutical ingredient, or a pharmaceutically acceptable salt thereof, and a geopolymeric binder.

### Claim 2 (depends on 1)

A composition as claimed in claim 1, characterised in that the active pharmaceutical ingredient is combined with the geopolymeric binder during the formation of that binder.

### Claim 3 (depends on 1)

A composition as claimed in claim 1, wherein the active pharmaceutical ingredient is an opioid analgesic.

### Claim 4 (depends on 3)

A composition as claimed in claim 3, wherein the opioid analgesic is selected from buprenorphine, alfentanil, sufentanil, remifentanil and fentanyl.

### Claim 5 (depends on 4)

A composition as claimed in claim 4, wherein the opioid analgesic is fentanyl.

### Claim 6 (depends on 1)

A process for the preparation of a composition as defined in claim 1, which comprises reaction of an aluminosilicate precursor material with an aqueous alkaline liquid.

### Claim 7 (depends on 6)

A process as claimed in claim 6, wherein the reaction is performed in the presence of a source of silica.

### Claim 8 (depends on 6, 7)

A process as claimed in claim 6 or claim 7, wherein the aluminosilicate precursor material is metakaolin.

### Claim 9 (depends on 6)

A process as claimed in claim 6, wherein the aluminosilicate precursor material is in the form of a powder with a grain size that is below about 30 μm.

### Claim 10 (depends on 6)

A process as claimed in claim 6, wherein the aqueous alkaline liquid comprises silicate.

### Claim 11 (depends on 6)

A process as claimed in claim 6, wherein the geopolymer material is formed by curing at about 40° C.

### Claim 12 (depends on 6)

A composition obtainable by a process as defined in claim 6.

### Claim 13 (depends on 1)

A composition as defined in claim 1 for use as a medicine.

### Claim 14 (depends on 3)

A composition as defined in claim 3 for use in the treatment of pain.

### Claim 15 (depends on 3)

The use of a composition as defined in claim 3 for the manufacture of a medicament for the treatment of pain.

### Claim 16 (depends on 3)

A method of treatment of pain which comprises administration of a composition as defined in claim 3 to a person suffering from, or susceptible to, such a condition.

### Claim 17

A sustained release medical composition prepared from:
(a) a powder composition comprising at least an aluminosilicate phase, said phase being optionally selected from the group: kaolin, dickite, halloysite, nacrite, zeolite, Illite, preferably dehydroxylated zeolite, halloysite or kaolin, and most preferably metakaolin;
(b) a water alkaline based liquid; and
(c) a medical active pharmaceutical ingredient (API).

### Claim 18 (depends on 17)

A tablet produced by a process of:
(i) forming a paste of said medical composition according to claim 17, to form a medical composition,
(ii) granulating said medical composition, and
(iii) hardening the granulate, and
(iv) forming a tablet of the hardened medical composition.

### Claim 19 (depends on 18)

A method of treating or preventing a disease comprising administrating of a tablet according to claim 18 to a subject in the need thereof, wherein said medical active pharmaceutical ingredient treats or prevents said disease.
